Stockscreener 앱 받기
0.178
3.99%
-0.0074
시간 외 거래:
.18
0.002
+1.12%
전일 마감가:
$0.1854
열려 있는:
$0.181
하루 거래량:
323.84K
Relative Volume:
0.05
시가총액:
$10.74M
수익:
-
순이익/손실:
$-35.80M
주가수익비율:
-0.0599
EPS:
-2.97
순현금흐름:
$-37.18M
1주 성능:
+1.14%
1개월 성능:
-21.65%
6개월 성능:
-64.33%
1년 성능:
-91.48%
1일 변동 폭
$0.1748
$0.1843
1주일 범위
$0.1722
$0.1944
52주 변동 폭
$0.13
$2.1568
Aptose Biosciences Inc Stock (APTO) Company Profile
명칭
Aptose Biosciences Inc
전화
310-849-8060
주소
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
APTO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.178 | 10.74M | 0 | -35.80M | -37.18M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-10-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-02-20 | 개시 | Maxim Group | Buy |
| 2020-02-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | Piper Sandler | Overweight |
| 2019-03-01 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-16 | 개시 | B. Riley FBR | Buy |
| 2017-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-23 | 재개 | ROTH Capital | Buy |
| 2017-09-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2017-06-08 | 개시 | Rodman & Renshaw | Neutral |
모두보기
Aptose Biosciences Inc 주식(APTO)의 최신 뉴스
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com - Defense World
Aptose Biosciences shareholders approve reverse stock split By Investing.com - Investing.com Canada
Aptose Biosciences Inc. (NASDAQ:APTO) Sees Large Increase in Short Interest - Defense World
Zura Bio (NASDAQ:ZURA) vs. Aptose Biosciences (NASDAQ:APTO) Critical Contrast - Defense World
Certain Common Shares of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-JAN-2025. - Marketscreener.com
Aptose Biosciences faces Nasdaq delisting over share price - MSN
Aptose Biosciences faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa
Aptose Biosciences Inc. Files 8-K Report - Defense World
Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com - Defense World
Aptose Biosciences Inc. Issues Regulation FD Disclosure in Recent Press Release - Defense World
Aptose Biosciences (NASDAQ:APTO) Earns “Buy” Rating from HC Wainwright - Defense World
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial - The Manila Times
Aptose Biosciences Initiates TUSCANY Trial for Frontline AML Therapy - TipRanks
Aptose Launches TUSCANY Trial: Groundbreaking Triple Therapy for Untreated AML Patients - StockTitan
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
Aptose Biosciences (NASDAQ: APTO) Announces Regulation FD DisclosureOn December 19, 2024, Aptose Biosciences Inc. issued a press release, providing detailed information on recent developments. The press release specified various financial results - Defense World
Aptose Announces Positive Decision by Nasdaq Hearings Panel - The Manila Times
Aptose gets Nasdaq extension to regain compliance - MSN
Aptose Biosciences Secures Critical Nasdaq Extension, Unveils $8M Offering and Cancer Drug Progress - StockTitan
Metrics That Matter About Aptose Biosciences Inc (NASDAQ: APTO) - Stocks Register
SEC Form PRE 14A filed by Aptose Biosciences Inc. - Quantisnow
Tuspetinib shows promise in AML treatment, study finds By Investing.com - Investing.com UK
Aptose Announces Publication of Preclinical Data in AACR - GlobeNewswire
Aptose's Tuspetinib Shows Breakthrough Potential in Leukemia Treatment, Clinical Data Reveals Powerful Anti-Cancer Effects - StockTitan
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax - Yahoo Finance
Aptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks On TSX (APS) - Barchart
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML - The Manila Times
Aptose Clinical Data Featured in Poster Presentation at the - GlobeNewswire
StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences maintains shares target, Buy rating post-NCI deal By Investing.com - Investing.com Canada
Likelihood of Approval and Phase Transition Success Rate ModelTuspetinib in Chronic Myelomonocytic Leukemia (CMML) - GlobalData
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials - The Manila Times
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML - GlobeNewswire
Aptose Partners with NCI to Advance Tuspetinib Cancer Treatment in Clinical Trials - StockTitan
Aptose Biosciences Inc (APTO) Has A Gold Mine On Its Hands - Stocks Register
Aptose Biosciences CEO William Rice acquires $20,000 in shares By Investing.com - Investing.com Australia
Aptose Biosciences CEO William Rice acquires $20,000 in shares - Investing.com
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering - GlobeNewswire
Aptose Biosciences Boosts Capital with $8M Offering - TipRanks
Aptose Biosciences Completes $8M Public Offering with Insider Participation | APTO Stock News - StockTitan
Form 424B4 Aptose Biosciences Inc. - StreetInsider.com
SEC Form 424B4 filed by Aptose Biosciences Inc. - Quantisnow
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Aptose sets $8 million target in stock and warrant offering By Investing.com - Investing.com Australia
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views - Benzinga
Aptose sets $8 million target in stock and warrant offering - Investing.com India
Aptose Biosciences Inc (APTO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
자본화:
|
볼륨(24시간):